Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2022 | Upcoming plasma biomarkers for Alzheimer’s disease: Aβ, p-tau and GFAP

Pamela Lukasewicz Ferreira, PhD, University of Pittsburgh, Pittsburgh, PA, provides an overview of the different Alzheimer’s disease biomarkers. Amyloid-beta (Aβ) is an established biomarker used in CSF lumbar puncture, but when used in blood, it is not very consistent. p-tau-217, p-tau-181, and p-tau-231 are the closest biomarkers to be used in a clinical setting, as a robust method has been identified which can predict Alzheimer’s disease with high accuracy. Glial fibrillary acidic protein (GFAP) requires more research as it is not specific to Alzheimer’s disease; it will be most useful when used in combination with other biomarkers. This interview took place at the AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases hosted in Barcelona, Spain.